Bicara Therapeutics Inc. Common Stock (BCAX) vs Replimune Group, Inc. (REPL)

A side-by-side comparison of Bicara Therapeutics Inc. Common Stock and Replimune Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Bicara Therapeutics Inc. Common Stock logo
BCAX
Bicara Therapeutics Inc. Common Stock
$1.09B
$16.56HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Replimune Group, Inc. logo
REPL
Replimune Group, Inc.
$1.11B
$13.25HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — BCAX vs REPL

growth of $100 · dividends reinvested · last 2y
BCAX -26.1% (-14.1%/yr)REPL +26.8% (+12.6%/yr)REPL compounded faster over this window
50100150Start $10020252026$74$127
BCAX REPL

BCAX vs REPL: by the numbers

  • •REPL is the larger company ($1.11B vs $1.09B market cap).

Metrics side by side

Valuation

MetricBCAXREPL
P/B ratio2.3210.54

Profitability

MetricBCAXREPL
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-39.54%-281.14%
ROIC-42.98%-139.11%

Growth (annualized)

MetricBCAXREPL
Total return CAGR (5Y)N/A-15.17%

Go deeper

Full BCAX analysisFull REPL analysisInteractive comparison tool

Dig into the metrics

Bicara Therapeutics Inc. Common Stock ROEReplimune ROEBicara Therapeutics Inc. Common Stock operating marginReplimune operating marginBicara Therapeutics Inc. Common Stock revenue growthReplimune revenue growthBicara Therapeutics Inc. Common Stock free cash flowReplimune free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.